Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic antibody technology 97

J W Larrick1, J Gavilondo

  • 1Palo Alto Institute of Molecular Medicine, Mountain View, CA 94043, USA.

Immunotechnology : an International Journal of Immunological Engineering
|April 8, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contrasting effects of Na+, K+-ATPase activation on seizure activity in acute versus chronic models.

Neuroscience·2015
Same author

Clinical trial of a plant-derived antibody on recolonization of mutans streptococci.

Caries research·2005
Same author

Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.

Clinical immunology (Orlando, Fla.)·2001
Same author

Production of secretory IgA antibodies in plants.

Biomolecular engineering·2001
Same author

Producing proteins in transgenic plants and animals.

Current opinion in biotechnology·2001
Same author

Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids.

Biophysical journal·2001
Same journal

Complementarity-determining region (CDR) implantation: a theme of recombination.

Immunotechnology : an international journal of immunological engineering·1999
Same journal

Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy.

Immunotechnology : an international journal of immunological engineering·1999
Same journal

Sequence-specific antibodies against human IgE isoforms induced by an epitope display system.

Immunotechnology : an international journal of immunological engineering·1999
Same journal

Properties and pharmacokinetics of two humanized antibodies specific for L-selectin.

Immunotechnology : an international journal of immunological engineering·1999
Same journal

An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.

Immunotechnology : an international journal of immunological engineering·1999
Same journal

An scFv phage clone that binds to human beta2-microglobulin.

Immunotechnology : an international journal of immunological engineering·1999
See all related articles

The Therapeutic Antibody Technology 97 meeting showcased advancements in antibody technology, including the development of the first commercially available catalytic antibody using reactive immunization. Future meetings and a Virtual Antibody Society are planned.

Area of Science:

  • Biotechnology
  • Immunology
  • Biochemistry

Background:

  • The Therapeutic Antibody Technology 97 meeting convened nearly 200 experts in antibody research.
  • The event focused on the latest developments in therapeutic antibody technology.
  • Organizers included the Palo Alto Institute of Molecular Medicine and the Scripps Research Institute.

Framework:

  • Discussions covered numerous talks and poster presentations on antibody technology.
  • A keynote address on 'Catalytic Antibodies' was delivered by Richard Lerner.
  • The development of catalytic antibodies through reactive immunization was a key topic.

Implementation:

  • Researchers presented work on generating a high-activity aldolase catalytic antibody.
  • This catalytic antibody is the first to be commercially available.

Related Experiment Videos

  • The findings are soon to be published in the journal Science.

    • Implications:

    • The meeting highlighted significant progress in the field of therapeutic antibodies.
    • Plans are underway to establish a 'Virtual Antibody Society' for continued collaboration.
    • Future meetings are anticipated to further advance antibody technology and applications.